OmniPLEX will be used in Kreatech’s Poseidon line of probes.

Rubicon Genomics signed a supply agreement with Kreatech Diagnostics for use of Rubicon’s OmniPLEX-D whole genome amplification technology. Under terms of the agreement Rubicon will provide reagents incorporating elements of its OmniPLEX® amplification technology to Kreatech for use in the manufacture of Kreatech’s Poseidon™ fluorescence in situ hybridization (FISH) probes.

“This new agreement further demonstrates the broad applicability of our suite of pre-analytical amplification technologies for producing superior results in nucleic acid detection and analysis,” notes James Koziarz, CEO of Rubicon. “By incorporating key elements of our technology into its manufacturing process, Kreatech is able to enhance the reliability, efficiency, and reproducibility of production of its FISH probes.”

Herman Volkers, COO of Kreatech, adds, “Kreatech’s Poseidon Repeat-Free technology eliminates repetitive elements in DNA FISH probes and in combination with our labeling technology—the ULS™ technology—delivers results that have less background, more specificity, and a brighter signal. Use of Rubicon’s pre-analytical amplification reagents during the production process contributes to achievement of this superior performance.”

The Repeat-Free technology eliminates the use of Cot-1 or blocking DNA, providing less background and a brighter signal. Kreatech’s ULS, or Universal Linkage System, is a nonenzymatic technology that has been leveraged in microarray labeling applications.

Rubicon’s OmniPLEX family of amplification technologies is designed to deliver sufficient quantities of high-quality species-specific or locus-specific RNA or DNA to increase the sensitivity and specificity of analyses of biological samples for biomedical research and clinical medicine. They use proprietary methods to prepare samples for sensitive and accurate PCR, microarray, and next-generation sequencing analysis and provide exceptional consistency, superior performance, and proven sensitivity, according to the company.

Previous articleSmall Molecule Inhibitors Dramatically Boost Efficiency of Fibroblast to Neuron Conversion
Next articleSeattle, Millennium Tap Ventana to Develop Companion Dx for Lymphoma Drug